Sign In
Buy OPT
$3.41
+0 (+0%)
At Close: Jun 30, 2025
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
05:30am, Friday, 27'th Oct 2023
Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors
Opthea to Participate at the 2023 Euretina Congress
05:30am, Monday, 02'nd Oct 2023
MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05:30am, Thursday, 07'th Sep 2023
MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progr
Opthea to Present at the 2023 Ophthalmology Innovation Summit
06:00am, Monday, 24'th Jul 2023
MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre
Opthea to Present at the Jefferies 2023 Healthcare Conference
06:00am, Thursday, 25'th May 2023
MELBOURNE, Australia, May 25, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progres
Opthea To Present at the JMP Securities Life Sciences Conference
05:30am, Monday, 08'th May 2023
MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progres
Opthea To Present at SVB Leerink Global Biopharma Conference
06:00am, Monday, 06'th Feb 2023
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre
Opthea To Present at Sequire Biotechnology Conference
06:00am, Monday, 30'th Jan 2023
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
10:08am, Monday, 12'th Dec 2022
MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre
Opthea to Present at the FLORetina 2022 Congress
06:00am, Tuesday, 06'th Dec 2022
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre
Optiva Inc. (RKNEF) Q3 2022 Earnings Call Transcript
12:13pm, Saturday, 12'th Nov 2022
Optiva Inc. (OTCPK:RKNEF) Q3 2022 Results Conference Call November 9, 2022 8:30 AM ET Company Participants Ali Mahdavi - Investor Relations John Giere - President and CEO Dinesh Sharma - VP of Finance
Opthea to Present at Jefferies London Healthcare Conference
06:00am, Thursday, 10'th Nov 2022
MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre
Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
07:46am, Tuesday, 16'th Aug 2022
MELBOURNE, Australia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre
Optiva Inc. (RKNEF) CEO John Giere on Q2 2022 Results - Earnings Call Transcript
02:16pm, Wednesday, 10'th Aug 2022
Optiva Inc. (OTCPK:RKNEF) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Ali Mahdavi - Investor Relations John Giere - Chief Executive Officer Dinesh Sharma - Vice Pr
Opthea To Present at Upcoming Investor Conferences
08:00am, Wednesday, 11'th May 2022
MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal
